Aquestive Therapeutics, Inc. (AQST)
| Market Cap | 611.24M +21.4% |
| Revenue (ttm) | 54.09M +22.6% |
| Net Income | -78.23M |
| EPS | -0.65 |
| Shares Out | 125.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,364 |
| Open | 4.870 |
| Previous Close | 4.810 |
| Day's Range | 4.830 - 4.870 |
| 52-Week Range | 2.930 - 7.550 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 9.33 (+91.58%) |
| Earnings Date | Nov 4, 2026 |
About AQST
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form ... [Read more]
Financial Performance
In 2025, Aquestive Therapeutics's revenue was $44.55 million, a decrease of -22.61% compared to the previous year's $57.56 million. Losses were -$83.78 million, 89.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price target is $9.33, which is an increase of 91.58% from the latest price.
News
Aquestive Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Anaphylm, an oral epinephrine film, is positioned for launch with strong clinical differentiation, robust commercial and financial readiness, and imminent FDA resubmission. The product targets significant unmet needs in an expanding market, with a disciplined strategy focused on key prescribers and patient access.
Aquestive Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Anaphylm, a sublingual film for severe allergic reactions, is poised for FDA resubmission with improved packaging and strong clinical data showing rapid onset and robust efficacy. The company is launch-ready with secured financing, a targeted commercial strategy, and a focus on payer engagement to highlight clinical and economic benefits.
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...
Aquestive Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth and improved EBITDA loss, driven by higher manufacturing and royalty income. Anaphylm's NDA resubmission is on track, with positive human factors and PK data addressing FDA concerns. Cash position and new debt facility support launch readiness.
Aquestive Therapeutics Earnings release: Q2 2026
Aquestive Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Aquestive Therapeutics Quarterly report: Q2 2026
Aquestive Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Aquestive Therapeutics Slides: Q2 2026
Aquestive Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
Aquestive Therapeutics reports Q2 EPS (18c), consensus (12c)
Reports Q2 revenue $13.82M, consensus $11.56M. “The epinephrine rescue market continues to grow and remains available for conversion from older medical device technology including autoinjectors,” said...
Aquestive Therapeutics backs FY26 revenue view $46M-$50M, consensus $50.51M
Backs FY26 adjusted EBITDA loss view $30M-$35M. “We also continue to expand our understanding of our AdrenaVerse epinephrine prodrug platform and the opportunity it presents,” continued Daniel Barber....
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement...
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026 Self-administration pharmacokinetic (PK) results were comparable to clinician-admini...
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Aquestive Therapeutics files to sell 230,271 shares of common stock for holders
16:21 EDT Aquestive Therapeutics (AQST) files to sell 230,271 shares of common stock for holders
Aquestive Therapeutics Registration statement: Registration filing
Aquestive Therapeutics filed a registration statement on June 26, 2026, providing details about a securities offering with the SEC.
Aquestive Therapeutics Transcript: AGM 2026
The meeting highlighted progress toward FDA approval and commercial launch of Anaphylm, global regulatory advances, and pipeline development. All shareholder proposals passed with strong support, and no material non-public information was disclosed during the Q&A.
Aquestive Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth, narrowed losses, and major regulatory progress for Anaphylm, with a robust cash position and new financing supporting launch readiness. International filings are on track, and early AQST-108 data show promise in dermatology.
Aquestive Therapeutics Earnings release: Q1 2026
Aquestive Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Aquestive Therapeutics Quarterly report: Q1 2026
Aquestive Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Aquestive Therapeutics Slides: Q1 2026
Aquestive Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Aquestive Therapeutics reports Q1 EPS (7c), consensus (13c)
Reports Q1 revenue $14.45M, consensus $10.9M. “We made rapid and meaningful progress in the first quarter,” said Daniel Barber, President and Chief Executive Officer of Aquestive. “We successfully com...
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Aquestive Therapeutics Proxy statement: Proxy filing
Aquestive Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.